HHS Pledges More Drug IP Transparency After Critical Report

The U.S. Department of Health and Human Services will begin publicly reporting more information on its licensing of intellectual property to private companies for drug development, following criticism from a congressional watchdog.

HHS, in a letter to the Government Accountability Office, said it would be more transparent with granting private companies licenses to government-owned drug and vaccine patents. The letter was attached to the GAO’s report, released Friday, on the department’s use of taxpayer dollars to fund drug development.

HHS said it will develop a plan within the first quarter of fiscal year 2021 for providing more information about ...